1287 related articles for article (PubMed ID: 19665609)
1. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
2. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
[TBL] [Abstract][Full Text] [Related]
4. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.
Etemad B; Batra G; Raut R; Dahiya S; Khanam S; Swaminathan S; Khanna N
Am J Trop Med Hyg; 2008 Sep; 79(3):353-63. PubMed ID: 18784226
[TBL] [Abstract][Full Text] [Related]
5. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes.
Khanam S; Rajendra P; Khanna N; Swaminathan S
BMC Biotechnol; 2007 Feb; 7():10. PubMed ID: 17302980
[TBL] [Abstract][Full Text] [Related]
6. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
[TBL] [Abstract][Full Text] [Related]
7. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.
Khanam S; Khanna N; Swaminathan S
Vaccine; 2006 Oct; 24(42-43):6513-25. PubMed ID: 16860446
[TBL] [Abstract][Full Text] [Related]
8. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.
Sim AC; Lin W; Tan GK; Sim MS; Chow VT; Alonso S
Vaccine; 2008 Feb; 26(9):1145-54. PubMed ID: 18243432
[TBL] [Abstract][Full Text] [Related]
9. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes.
Khanam S; Etemad B; Khanna N; Swaminathan S
Am J Trop Med Hyg; 2006 Feb; 74(2):266-77. PubMed ID: 16474083
[TBL] [Abstract][Full Text] [Related]
10. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
[TBL] [Abstract][Full Text] [Related]
11. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.
Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C
Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370
[TBL] [Abstract][Full Text] [Related]
12. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.
Block OK; Rodrigo WW; Quinn M; Jin X; Rose RC; Schlesinger JJ
Vaccine; 2010 Nov; 28(51):8085-94. PubMed ID: 20959154
[TBL] [Abstract][Full Text] [Related]
13. Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.
Raja NU; Holman DH; Wang D; Raviprakash K; Juompan LY; Deitz SB; Luo M; Zhang J; Porter KR; Dong JY
Am J Trop Med Hyg; 2007 Apr; 76(4):743-51. PubMed ID: 17426182
[TBL] [Abstract][Full Text] [Related]
14. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
15. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
16. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.
Holman DH; Wang D; Raviprakash K; Raja NU; Luo M; Zhang J; Porter KR; Dong JY
Clin Vaccine Immunol; 2007 Feb; 14(2):182-9. PubMed ID: 17192403
[TBL] [Abstract][Full Text] [Related]
17. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
18. Expression, purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen.
Batra G; Talha SM; Nemani SK; Dhar N; Swaminathan S; Khanna N
Protein Expr Purif; 2010 Nov; 74(1):99-105. PubMed ID: 20435144
[TBL] [Abstract][Full Text] [Related]
19. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
[TBL] [Abstract][Full Text] [Related]
20. Domain III of the envelope protein as a dengue vaccine target.
Guzman MG; Hermida L; Bernardo L; Ramirez R; Guillén G
Expert Rev Vaccines; 2010 Feb; 9(2):137-47. PubMed ID: 20109025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
